Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 8:19:e20190018.
doi: 10.1590/1677-5449.190018.

Alopecia in anticoagulated patients

Marcos Arêas Marques  1 , Carmen Lucia Lascasas Porto  1 , Ana Letícia de Matos Milhomens  1 , Juliana de Miranda Vieira  1 , Claudia Carvalho Alcântara Gomes  2 , Ana Thereza Cavalcanti Rocha  3 , Cíntia da Silva Miller  1
Affiliations
Review

Alopecia in anticoagulated patients

Marcos Arêas Marques et al. J Vasc Bras. .

Abstract
in English, Portuguese

Alopecia is a common complication of anticoagulant therapy that may have important psychological repercussions for patients, especially female patients, and can interfere with the decision to extend anticoagulation. This review aims to describe the mechanisms potentially involved in the genesis of alopecia during anticoagulant therapy, since these are not yet fully understood, and discusses the existing therapies for the most appropriate management.

Resumo: A alopecia é uma complicação comum da terapia anticoagulante que pode ter repercussões psicológicas importantes nos pacientes, especialmente nos do sexo feminino, e interferir na decisão de extensão da anticoagulação. Esta revisão tem como objetivo descrever os mecanismos potencialmente envolvidos na gênese da alopecia durante a terapia anticoagulante, pois eles ainda não estão totalmente esclarecidos, e as terapias existentes, para a adoção das condutas mais adequadas.

Keywords: alopecia; anticoagulants; drug-related side effects and adverse reactions; heparin; rivaroxaban; warfarin.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: No conflicts of interest declared concerning the publication of this article.

References

    1. World Health Organization VigiBase: the database of suspected adverse reaction reports. 2017. [citado 2017 mar 13]. http://vigiaccess.org/
    1. Wang YY, Po HL. Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Ther. 2006;31(5):513–517. doi: 10.1111/j.1365-2710.2006.00769.x. - DOI - PubMed
    1. Christopoulou EC, Filippatos TD, Elisaf MS. Non-haemorrhage-related adverse effects of rivaroxaban. Arch Med Sci Atheroscler Dis. 2017;2(2):108–112. doi: 10.5114/amsad.2017.72533. - DOI - PMC - PubMed
    1. Chretien B, Besnard A, Sassier M, et al. Rivaroxaban-induced hair loss. Eur J Clin Pharmacol. 2015;71(11):1413–1414. doi: 10.1007/s00228-015-1927-7. - DOI - PubMed
    1. Watras MM, Patel JP, Arya R. Traditional anticoagulants and hair loss: a role for direct oral anticoagulants? A review of the literature. Drugs Real World Outcomes. 2016;3(1):1–6. doi: 10.1007/s40801-015-0056-z. - DOI - PMC - PubMed

LinkOut - more resources